company background image
REGN logo

Regeneron Pharmaceuticals NasdaqGS:REGN Stock Report

Last Price

US$989.28

Market Cap

US$106.3b

7D

4.5%

1Y

30.1%

Updated

27 Feb, 2024

Data

Company Financials +

Regeneron Pharmaceuticals, Inc.

NasdaqGS:REGN Stock Report

Market Cap: US$106.3b

REGN Stock Overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

REGN fundamental analysis
Snowflake Score
Valuation4/6
Future Growth1/6
Past Performance2/6
Financial Health5/6
Dividends0/6

Regeneron Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Regeneron Pharmaceuticals
Historical stock prices
Current Share PriceUS$989.28
52 Week HighUS$995.97
52 Week LowUS$684.81
Beta0.11
1 Month Change5.24%
3 Month Change22.35%
1 Year Change30.10%
3 Year Change117.49%
5 Year Change126.31%
Change since IPO4,582.98%

Recent News & Updates

Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings

Feb 16
Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings

Recent updates

Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings

Feb 16
Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings

Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024

Feb 10

Regeneron's Push Into Obesity, Q4 2023 Earnings Review

Feb 02

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Jan 31
These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?

Oct 25
Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 52% Above Its Share Price

Aug 07
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 52% Above Its Share Price

Regeneron Pharmaceuticals (NASDAQ:REGN) Has A Pretty Healthy Balance Sheet

Jul 17
Regeneron Pharmaceuticals (NASDAQ:REGN) Has A Pretty Healthy Balance Sheet

Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?

Apr 17
Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 46% Above Its Share Price

Feb 03
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 46% Above Its Share Price

We Think Regeneron Pharmaceuticals (NASDAQ:REGN) Can Stay On Top Of Its Debt

Jan 16
We Think Regeneron Pharmaceuticals (NASDAQ:REGN) Can Stay On Top Of Its Debt

Shareholder Returns

REGNUS BiotechsUS Market
7D4.5%3.4%1.8%
1Y30.1%10.7%25.1%

Return vs Industry: REGN exceeded the US Biotechs industry which returned 10.7% over the past year.

Return vs Market: REGN exceeded the US Market which returned 25.1% over the past year.

Price Volatility

Is REGN's price volatile compared to industry and market?
REGN volatility
REGN Average Weekly Movement2.4%
Biotechs Industry Average Movement11.6%
Market Average Movement6.1%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.1%

Stable Share Price: REGN has not had significant price volatility in the past 3 months.

Volatility Over Time: REGN's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198813,450Leonard Schleiferhttps://www.regeneron.com

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.

Regeneron Pharmaceuticals, Inc. Fundamentals Summary

How do Regeneron Pharmaceuticals's earnings and revenue compare to its market cap?
REGN fundamental statistics
Market capUS$106.31b
Earnings (TTM)US$3.95b
Revenue (TTM)US$13.12b

26.9x

P/E Ratio

8.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
REGN income statement (TTM)
RevenueUS$13.12b
Cost of RevenueUS$6.25b
Gross ProfitUS$6.86b
Other ExpensesUS$2.91b
EarningsUS$3.95b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)36.79
Gross Margin52.32%
Net Profit Margin30.14%
Debt/Equity Ratio7.6%

How did REGN perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.